IHL-493c is a novel, patent-pending investigational drug designed and formulated for the sole purpose of treating TMJD transdermally
The National Institutes of Health (NIH) and the National Institute of Dental and Craniofacial Research (NIDCR) estimate that $4 billion is spent every year on the diagnosis and treatment of temporomandibular joint dysfunction in the USA alone.
Despite signs of TMJD being common, the reported prevalence of symptomatic disease requiring treatment occurs in only 5% to 12% of the population